These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19015251)

  • 1. Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine.
    Wipasa J; Xu H; Liu X; Hirunpetcharat C; Stowers A; Good MF
    Infect Immun; 2009 Feb; 77(2):817-24. PubMed ID: 19015251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
    Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.
    Stanisic DI; Martin LB; Liu XQ; Jackson D; Cooper J; Good MF
    Infect Immun; 2003 Oct; 71(10):5700-13. PubMed ID: 14500491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.
    Kawabata Y; Udono H; Honma K; Ueda M; Mukae H; Kadota J; Kohno S; Yui K
    Infect Immun; 2002 Nov; 70(11):6075-82. PubMed ID: 12379684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria.
    Wipasa J; Hirunpetcharat C; Mahakunkijcharoen Y; Xu H; Elliott S; Good MF
    J Immunol; 2002 Jul; 169(2):944-51. PubMed ID: 12097400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
    Singh B; Cabrera-Mora M; Jiang J; Galinski M; Moreno A
    Vaccine; 2010 Mar; 28(14):2580-92. PubMed ID: 20097151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
    Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
    Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.
    Wipasa J; Xu H; Makobongo M; Gatton M; Stowers A; Good MF
    Infect Immun; 2002 Nov; 70(11):6013-20. PubMed ID: 12379677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
    Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
    PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.
    Sakai T; Hisaeda H; Nakano Y; Zhang M; Takashima M; Ishii K; Maekawa Y; Matsumoto S; Nitta Y; Miyazaki Ji; Yamamoto S; Himeno K
    Vaccine; 2003 Mar; 21(13-14):1432-44. PubMed ID: 12615440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response.
    Hensmann M; Li C; Moss C; Lindo V; Greer F; Watts C; Ogun SA; Holder AA; Langhorne J
    Eur J Immunol; 2004 Mar; 34(3):639-648. PubMed ID: 14991593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
    Ahlborg N; Ling IT; Holder AA; Riley EM
    Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
    Tian JH; Kumar S; Kaslow DC; Miller LH
    Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
    Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
    Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
    Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
    J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
    Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF
    J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
    Near KA; Stowers AW; Jankovic D; Kaslow DC
    Infect Immun; 2002 Feb; 70(2):692-701. PubMed ID: 11796601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.